Sadamoto Zenda1, Tetsuo Akimoto2, Masashi Mizumoto3, Ryuichi Hayashi4, Satoko Arahira2, Toshiyuki Okumura3, Hideyuki Sakurai3. 1. Department of Radiation Oncology, National Cancer Center Hospital East, Japan. Electronic address: szenda@east.ncc.go.jp. 2. Department of Radiation Oncology, National Cancer Center Hospital East, Japan. 3. Department of Radiation Oncology & Proton Medical Research Center, United States. 4. Head and Neck Surgery, National Cancer Center Hospital East, Japan.
Abstract
PURPOSE: The aim of this phase II study was to assess the clinical benefit of proton beam therapy for mucosal melanoma of the nasal cavity and para-nasal sinuses. MATERIALS AND METHODS: N0M0 mucosal melanoma of the nasal cavity and para-nasal sinuses were enrolled. Proton therapy was delivered three times per week with a planned total dose of 60 GyE in 15 fractions. Primary endpoint was local control rate at 1 year after treatment. Based on the results of a pilot study, the local control rate was estimated at 75%. RESULTS: Thirty-two patients were enrolled from June 2008 through October 2012. Patient characteristics were as follows: median age 73 years (range, 36-89 years); male/female ratio, 12/20; and T stage 3/4, 11/21. Local control rate at 1 year was 75.8% (95% CI: 63.8-92.4%). With a median follow-up period of 36.4 months, 3-year overall survival rate was 46.1%. The most frequent pattern of first failure was distant metastasis. The main cause of death was cancer death due to distant metastases (93.3%). CONCLUSIONS: Proton beam therapy showed sufficient local control benefits for mucosal melanoma as an alternative treatment of surgery.
PURPOSE: The aim of this phase II study was to assess the clinical benefit of proton beam therapy for mucosal melanoma of the nasal cavity and para-nasal sinuses. MATERIALS AND METHODS: N0M0 mucosal melanoma of the nasal cavity and para-nasal sinuses were enrolled. Proton therapy was delivered three times per week with a planned total dose of 60 GyE in 15 fractions. Primary endpoint was local control rate at 1 year after treatment. Based on the results of a pilot study, the local control rate was estimated at 75%. RESULTS: Thirty-two patients were enrolled from June 2008 through October 2012. Patient characteristics were as follows: median age 73 years (range, 36-89 years); male/female ratio, 12/20; and T stage 3/4, 11/21. Local control rate at 1 year was 75.8% (95% CI: 63.8-92.4%). With a median follow-up period of 36.4 months, 3-year overall survival rate was 46.1%. The most frequent pattern of first failure was distant metastasis. The main cause of death was cancer death due to distant metastases (93.3%). CONCLUSIONS: Proton beam therapy showed sufficient local control benefits for mucosal melanoma as an alternative treatment of surgery.
Authors: Beata Sas-Korczynska; Marian Reinfuss; Jerzy W Mitus; Elzbieta Pluta; Anna Patla; Tomasz Walasek Journal: Rep Pract Oncol Radiother Date: 2018-08-17